MICHAEL CANTWELL: Open Payments
NPI 1750381059 · VINCENNES, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 29 payments from 12 companies in 2025. Trend: 2023 $515 · 2024 $477 · 2025 $710
Food & beverage: $572Education: $139
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $194 |
| Axsome Therapeutics, Inc. | 4 | $190 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| Alkermes, Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Biogen, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: Auvelity, FANAPT, INGREZZA, AUSTEDO XR, CAPLYTA, UZEDY, ARISTADA, ZURZUVAE.
Industry payments across IN — which companies pay providers there.
